164 related articles for article (PubMed ID: 37084286)
1. COVID-19 Developed During Systemic Steroid Therapy for Vogt-Koyanagi-Harada Disease: A Case Report.
Niidome S; Usui Y; Tsubota K; Sugawara R; Goto H
Ocul Immunol Inflamm; 2023 Aug; 31(6):1305-1309. PubMed ID: 37084286
[TBL] [Abstract][Full Text] [Related]
2. Vogt-Koyanagi-Harada Disease Exacerbation Associated with COVID-19 Vaccine.
De Domingo B; López M; Lopez-Valladares M; Ortegon-Aguilar E; Sopeña-Perez-Argüelles B; Gonzalez F
Cells; 2022 Mar; 11(6):. PubMed ID: 35326462
[TBL] [Abstract][Full Text] [Related]
3. Vogt-Koyanagi-Harada disease after SARS-CoV-2 infection: Case report and literature review.
Zou H; Zhang K; Chen X; Sha S
Immun Inflamm Dis; 2024 Apr; 12(4):e1250. PubMed ID: 38661242
[TBL] [Abstract][Full Text] [Related]
4. A COVID-19 perspective of Vogt-Koyanagi-Harada disease.
Dutta Majumder P; Sadhu S; González-López JJ; Mochizuki M
Indian J Ophthalmol; 2023 Jun; 71(6):2587-2591. PubMed ID: 37322685
[TBL] [Abstract][Full Text] [Related]
5. Vogt-Koyanagi-Harada Relapse after COVID-19 Vaccination.
Accorinti M; Saturno MC; Manni P
Ocul Immunol Inflamm; 2022 Jul; 30(5):1228-1233. PubMed ID: 35201950
[TBL] [Abstract][Full Text] [Related]
6. Possible Association between Vogt-Koyanagi-Harada Disease and Coronavirus Disease Vaccine: A Report of Four Cases.
de Queiroz Tavares Ferreira F; Araújo DC; de Albuquerque LM; Bianchini PM; Holanda EC; Pugliesi A
Ocul Immunol Inflamm; 2023 Aug; 31(6):1134-1140. PubMed ID: 35914285
[TBL] [Abstract][Full Text] [Related]
7. Multicenter, retrospective, observational study for the Treatment Pattern of systemic corticoSTERoids for relapse of non-infectious uveitis accompanying Vogt-Koyanagi-Harada disease or sarcoidosis.
Namba K; Takase H; Usui Y; Nitta F; Maruyama K; Kusuhara S; Takeuchi M; Azumi A; Yanai R; Kaneko Y; Hasegawa E; Nakai K; Tsuruga H; Morita K; Kaburaki T
Jpn J Ophthalmol; 2022 Mar; 66(2):130-141. PubMed ID: 35044561
[TBL] [Abstract][Full Text] [Related]
8. Vogt-Koyanagi-Harada Disease following mRNA-1273 (Moderna) COVID-19 Vaccination.
Joo CW; Kim YK; Park SP
Ocul Immunol Inflamm; 2022 Jul; 30(5):1250-1254. PubMed ID: 35404752
[TBL] [Abstract][Full Text] [Related]
9. The Relationship of Vogt-Koyanagi-Harada Syndrome to Ocular Hypertension and Glaucoma.
Veerappan M; Fleischman D; Ulrich JN; Stinnett SS; Jaffe GJ; Allingham RR
Ocul Immunol Inflamm; 2017 Dec; 25(6):748-752. PubMed ID: 27438521
[TBL] [Abstract][Full Text] [Related]
10. [Steroid Resistant Vogt-Koyanagi-Harada Disease Treated Effectively with Cyclosporine].
Fukutomi A; Mashimo H; Yoshioka M; Haruta M; Minami T; Shimojo H; Ohguro N
Nippon Ganka Gakkai Zasshi; 2017 Jun; 121(6):480-6. PubMed ID: 30088715
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of initial-onset acute uveitis associated with Vogt-Koyanagi-Harada disease occurred during pregnancy.
Alromaih AZ; Almater AI; Albloushi AF; Alkheraiji NF; Abu El-Asrar AM
Int Ophthalmol; 2023 Jan; 43(1):185-195. PubMed ID: 35945413
[TBL] [Abstract][Full Text] [Related]
12. Case with metastatic cutaneous malignant melanoma that developed Vogt-Koyanagi-Harada-like uveitis following pembrolizumab treatment.
Enomoto H; Kato K; Sugawara A; Itabashi M; Kondo M
Doc Ophthalmol; 2021 Jun; 142(3):353-360. PubMed ID: 33392895
[TBL] [Abstract][Full Text] [Related]
13. Mycophenolate mofetil combined with systemic corticosteroids prevents progression to chronic recurrent inflammation and development of 'sunset glow fundus' in initial-onset acute uveitis associated with Vogt-Koyanagi-Harada disease.
Abu El-Asrar AM; Dosari M; Hemachandran S; Gikandi PW; Al-Muammar A
Acta Ophthalmol; 2017 Feb; 95(1):85-90. PubMed ID: 27535102
[TBL] [Abstract][Full Text] [Related]
14. Case report: Bilateral panuveitis resembling Vogt-Koyanagi-Harada disease after second dose of BNT162b2 mRNA COVID-19 vaccine.
Sato T; Nihei R; Sora D; Nishio Y; Takeuchi M
Front Immunol; 2022; 13():967972. PubMed ID: 36248859
[TBL] [Abstract][Full Text] [Related]
15. Vogt-Koyanagi-Harada disease-like uveitis following nivolumab administration treated with steroid pulse therapy: a case report.
Kikuchi R; Kawagoe T; Hotta K
BMC Ophthalmol; 2020 Jun; 20(1):252. PubMed ID: 32580711
[TBL] [Abstract][Full Text] [Related]
16. Reversal of Peripheral Iris Depigmentation Associated with Vogt-Koyanagi-Harada Disease.
Tobaigy MF; AlBloushi AF; Al-Dhibi HA
Ocul Immunol Inflamm; 2024 May; 32(4):424-428. PubMed ID: 36657743
[TBL] [Abstract][Full Text] [Related]
17. Vogt-Koyanagi-Harada syndrome-like uveitis after nivolumab administration as a treatment for ovarian cancer.
Hwang GE; Lee JW; Jeon S; Cho IH; Kim HD
Doc Ophthalmol; 2022 Apr; 144(2):153-162. PubMed ID: 34997406
[TBL] [Abstract][Full Text] [Related]
18. Proliferative retinopathy as a feature of Vogt Koyanagi Harada Disease: a report of two cases.
Magliyah MS; Al-Fakhri AS; Al-Dhibi HA
BMC Ophthalmol; 2020 Dec; 20(1):470. PubMed ID: 33261580
[TBL] [Abstract][Full Text] [Related]
19. Vogt-Koyanagi-Harada Syndrome in a Canadian First Nations Population.
Kryshtalskyj MT; Roy M
Ocul Immunol Inflamm; 2022 May; 30(4):894-900. PubMed ID: 33621146
[TBL] [Abstract][Full Text] [Related]
20. The outcomes of mycophenolate mofetil therapy combined with systemic corticosteroids in acute uveitis associated with Vogt-Koyanagi-Harada disease.
Abu El-Asrar AM; Hemachandran S; Al-Mezaine HS; Kangave D; Al-Muammar AM
Acta Ophthalmol; 2012 Dec; 90(8):e603-8. PubMed ID: 22971163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
